Abstract:

Objective To evaluate the short⁃ and medium⁃term efficacy of drug⁃coated balloon（DCB）in the treatment of arteriovenous fistula stenosis. Methods The clinical data of 43 patients with arteriovenous fistula stenosis treated with endovascular therapy from May 2020 to December 2021 were retrospectively analyzed. Twenty⁃ two patients were treated with DCB（DCB group），and 21 patients with plain angioplasty balloon（PAB group）. Target lesion primary patency（TLPP），access circuit primary patency（ACPP），late lumen loss（LLL）and other indicators were compared between the two groups at 3，6，12 months after operation. Results The operation was successful in all cases. There was no significant difference in TLPP between the two groups 3 months after opera⁃ tion. The TLPP of DCB group was significantly higher than that of PAB group 6 and 12 months after operation ［（81.8% vs. 47.6%），（54.5% vs. 23.8%），both P < 0.05）］；there was no significant difference in ACPP between the two groups 3，6，12 months after operation；LLL 6 and 12 months after operation in DCB group was significant⁃ ly lower than that in PAB group（P < 0.05）. Conclusion DCB has a better clinical efficacy and significant advan⁃ tage over plain angioplasty balloon in the treatment of arteriovenous fistula.

Key words:

hemodialysis, arteriovenous fistula stenosis, percutaneous transluminal angioplasty, drug coated balloon